As of the latest Form 4 filed Jul 2, 2026.
What Roivant Sciences Ltd insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 57 most recent filings for ROIV.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-06-30 | Gline Matthew CEO | FTax | −76.2K | $35.39 | $2.70M | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Torti Frank President and Vant Chair | FTax | −40.3K | $35.39 | $1.43M | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Sukhatme Mayukh President & CIO | FTax | −46.9K | $35.39 | $1.66M | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Fitzgerald Meghan Director | SSale | −10.0K | $34.90 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Fitzgerald Meghan, Director | MExercise | +10.0K | $8.80 | $88.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Epperly Melissa B, Director | SSale | −2.75K | $34.71 | $95.4K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Epperly Melissa B,, Director | SSale | −15.0K | $34.32 | $515K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Epperly Melissa B,, Director | MExercise | +17.8K | $4.46 | $79.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | MANCHESTER KEITH S Director | SSale | −200K | $35.45 | $7.09M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | MANCHESTER KEITH S, Director | SSale | −12.4K | $35.28 | $437K | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | Gold Daniel Allen Director | SSale | −12.4K | $35.28 | $437K | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | QVT Financial LP Insider | SSale | −12.4K | $35.28 | $437K | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | MANCHESTER KEITH S Director | SSale | −600K | $34.59 | $20.8M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | MANCHESTER KEITH S, Director | SSale | −200K | $34.44 | $6.89M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Gold Daniel Allen Director | SSale | −600K | $34.59 | $20.8M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Gold Daniel Allen, Director | SSale | −200K | $34.44 | $6.89M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | QVT Financial LP Insider | SSale | −600K | $34.59 | $20.8M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | QVT Financial LP, Insider | SSale | −200K | $34.44 | $6.89M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | MANCHESTER KEITH S Director | SSale | −325K | $34.07 | $11.1M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | MANCHESTER KEITH S, Director | SSale | −301K | $33.92 | $10.2M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Gold Daniel Allen Director | SSale | −325K | $34.07 | $11.1M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Gold Daniel Allen, Director | SSale | −301K | $33.92 | $10.2M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | QVT Financial LP Insider | SSale | −325K | $34.07 | $11.1M | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | QVT Financial LP, Insider | SSale | −301K | $33.92 | $10.2M | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-26 | Sukhatme Mayukh President & CIO | SSale | −500K | $34.08 | $17.0M | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-26 | Sukhatme Mayukh, President & CIO | MExercise | +500K | $3.85 | $1.93M | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Sukhatme Mayukh, President & CIO | SSale | −500K | $34.13 | $17.1M | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Sukhatme Mayukh, President & CIO | MExercise | +500K | $3.85 | $1.93M | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Venker Eric President & Immunovant CEO | SSale | −46.2K | $33.51 | $1.55M | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Venker Eric, President & Immunovant CEO | SSale | −154K | $33.05 | $5.08M | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Venker Eric, President & Immunovant CEO | MExercise | +200K | $3.85 | $770K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-20 | Pulik Richard CFO | FTax | −2.13K | $31.43 | $66.9K | No | Form 4 ↗ |
| 2026-06-23 | 2026-06-20 | Humes Jennifer Chief Accounting Officer | FTax | −3.58K | $31.43 | $113K | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Venker Eric President & Immunovant CEO | SSale | −200K | $29.59 | $5.92M | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Venker Eric, President & Immunovant CEO | MExercise | +200K | $3.85 | $770K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Pulik Richard CFO | AAward | +60.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Humes Jennifer Chief Accounting Officer | AAward | +29.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Epperly Melissa B, Director | AAward | +670.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | MOMTAZEE JAMES C Director | FTax | −94.00 | $29.83 | $2.80K | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | MOMTAZEE JAMES C, Director | AAward | +469.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Oren Ilan Director | FTax | −95.00 | $29.83 | $2.83K | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Oren Ilan, Director | AAward | +896.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Gline Matthew CEO | SSale | −290K | $29.16 | $8.45M | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Humes Jennifer Chief Accounting Officer | SSale | −13.5K | $28.37 | $384K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Gline Matthew CEO | FTax | −305K | $27.70 | $8.44M | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Sukhatme Mayukh President & CIO | FTax | −188K | $27.70 | $5.19M | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Gline Matthew CEO | FTax | −53.8K | $26.41 | $1.42M | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Gline Matthew, CEO | MExercise | +97.3K | — | — | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Sukhatme Mayukh President & CIO | FTax | −29.8K | $26.41 | $787K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Sukhatme Mayukh, President & CIO | MExercise | +58.4K | — | — | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Fitzgerald Meghan Director | SSale | −70.0K | $27.45 | $1.92M | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Fitzgerald Meghan, Director | MExercise | +70.0K | $8.80 | $616K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Pulik Richard CFO | FTax | −1.55K | $27.70 | $42.8K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Humes Jennifer Chief Accounting Officer | FTax | −14.5K | $27.70 | $402K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Venker Eric President & Immunovant CEO | SSale | −200K | $28.24 | $5.65M | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Venker Eric, President & Immunovant CEO | MExercise | +200K | $3.85 | $770K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Epperly Melissa B, Director | SSale | −41.9K | $28.68 | $1.20M | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ROIV’s full analysis or the market-wide insider trading feed. The tabs above jump to ROIV’s other SEC data.
Source: SEC Form 4 filings for ROIV, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.